NCT06128460View on ClinicalTrials.gov

Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2029

Conditions
Cervical Cancer
Interventions
DRUG

Zimberelimab

240mg, q3w，8 cycles

DRUG

Platinum

cisplatin 40mg/m2 for 5-6 cycles

RADIATION

radiotherapy

45-50Gy/1.8Gy/25-28f

All Listed Sponsors
lead

Obstetrics & Gynecology Hospital of Fudan University

OTHER

NCT06128460 - Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. | Biotech Hunter | Biotech Hunter